Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $69.92 USD
Change Today -1.66 / -2.32%
Volume 461.0K
ABMD On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 8:10 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

abiomed inc (ABMD) Snapshot

Open
$71.14
Previous Close
$71.58
Day High
$71.27
Day Low
$68.55
52 Week High
03/24/15 - $74.70
52 Week Low
05/8/14 - $20.29
Market Cap
2.9B
Average Volume 10 Days
797.0K
EPS TTM
$0.49
Shares Outstanding
41.1M
EX-Date
--
P/E TM
143.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for ABIOMED INC (ABMD)

Related News

No related news articles were found.

abiomed inc (ABMD) Related Businessweek News

No Related Businessweek News Found

abiomed inc (ABMD) Details

ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP, a micro heart pump; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the Impella RP, a percutaneous catheter-based axial flow pump; and AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, it offers Symphony, a synchronized minimally invasive implantable cardiac assist device designed to treat chronic patients with moderate heart failure by improving patient hemodynamics; and AbioCor program. The company sells its products through direct sales and clinical support personnel in the United States, Canada, Germany, France, the United Kingdom, and internationally. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.

511 Employees
Last Reported Date: 05/28/14
Founded in 1981

abiomed inc (ABMD) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $519.7K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $315.9K
Chief Operating Officer
Total Annual Compensation: $341.8K
Vice President and General Manager of Global ...
Total Annual Compensation: $297.0K
Senior Vice President of Global Product Opera...
Total Annual Compensation: $284.6K
Compensation as of Fiscal Year 2014.

abiomed inc (ABMD) Key Developments

Abiomed, Inc.'s Impella 2.5 Receives U.S. Food and Drug Administration Approval for Elective and Urgent High Risk Percutaneous Coronary Intervention Procedures

Abiomed, Inc. announced that it has received U.S. Food and Drug Administration Pre-Market Approval for the Impella 2.5 heart pump during elective and urgent high risk percutaneous coronary intervention (PCI) procedures. This approval is based on the extensive clinical data submitted by Abiomed to the FDA to support this PMA as part of the 515 initiative. Impella 2.5, the heart pump, is the first hemodynamic support device to receive a PMA indication for use during high risk PCI procedures, demonstrating its safety and effectiveness for this complex patient population. With this approval, the Impella 2.5 is a temporary (= 6 hours) ventricular support device indicated for use during high risk PCI performed in elective or urgent hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction, when a heart team, including a cardiac surgeon, has determined high risk PCI is the appropriate therapeutic option. Use of the Impella 2.5 in these patients may prevent hemodynamic instability that may occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events. The product labeling allows for the clinical decision to leave Impella 2.5 in place beyond the intended duration of =6 hours due to unforeseen circumstances. Per the 2011 ACC/AHA guidelines, it is a Class 1 recommendation for a heart team, which includes a cardiac surgeon, to determine the treatment strategy for revascularization (either PCI or surgery). This decision is made based on a pre-defined institutional protocol or on a per patient basis. If the protocol determines that PCI is appropriate, Impella is the only hemodynamic support device proven safe and effective for high risk PCI. This heart team approach has also been utilized for the treatment strategy for heart valve replacement. In addition to the U.S. clinical trial data, the Impella 2.5 PMA submission included clinical and scientific supporting evidence from more than 215 publications, totaling 1,638 Impella 2.5 patients and incorporated a medical device reporting (MDR) analysis from 13,981 Impella 2.5 patients. In addition to PROTECT I and PROTECT II, further data was provided in the submission from 637 high risk patients enrolled in the U.S. Impella registry. The U.S. registry is an ongoing multicenter, observational retrospective registry including 49 centers. The data collection from the registry includes Institutional Review Board (IRB) approval, complete data monitoring and Clinical Events Committee adjudication. Additionally, the PMA analysis included hemodynamic science described in the literature and validated with a series of pre-clinical and clinical studies.

ABIOMED, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:00 PM

ABIOMED, Inc. Presents at Leerink's Global Healthcare Conference, Feb-11-2015 01:00 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Michael R. Minogue, Chairman, Chief Executive Officer, President, Member of Special Stock Option Committee and Member of Executive Committee.

Abiomed Inc Receives FDA HDE Approval for the Impella RP

Abiomed Inc. announced that the Impella RP® (Right Percutaneous) System has received U.S. Food and Drug Administration (FDA) approval under a Humanitarian Device Exemption (HDE). This innovative medical device is the first percutaneous single access heart pump designed for right heart support to receive FDA approval. Abiomed completed the HDE submission for the Impella RP in September 2014 following the completion of the RECOVER RIGHT study. Delivered through a catheter requiring only a small hole in the leg, the Impella RP is FDA indicated for providing circulatory assistance for up to 14 days in pediatric or adult patients who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery. These patients lack blood flow from the right side of their hearts. The Impella RP is designed to provide the flow and pressure needed to compensate for right heart failure. The device does not require a surgical procedure for insertion, and it provides up to four liters per minute of hemodynamic support. There will be a controlled launch of the Impella RP in the U.S. after each site completes in-house training at Abiomed. This rigorous training will incorporate members of the heart team, including the interventional cardiologist, cardiac surgeon, heart failure cardiologist and lead nurse.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABMD:US $69.92 USD -1.66

ABMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hansen Medical Inc $0.83 USD -0.04
LeMaitre Vascular Inc $8.27 USD -0.11
Stereotaxis Inc $2.04 USD -0.0101
Spectranetics Corp/The $34.35 USD -0.41
Thoratec Corp $41.63 USD -0.26
View Industry Companies
 

Industry Analysis

ABMD

Industry Average

Valuation ABMD Industry Range
Price/Earnings 100.0x
Price/Sales 13.7x
Price/Book 14.9x
Price/Cash Flow 159.6x
TEV/Sales 13.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABIOMED INC, please visit www.abiomed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.